COVID-19 Vaccine AstraZeneca Recommended for Use in the EU

29 January 2021 -- AstraZeneca’s COVID-19 vaccine has been recommended for conditional marketing authorisation (CMA) in the European Union (EU) for active immunisation to prevent COVID-19 caused by SA

Latest News Clinical News 1591
• Read All

FDA Approves Fotivda (tivozanib) for the Treatment of Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma

BOSTON--(BUSINESS WIRE) March 10, 2021 -- AVEO Oncology (Nasdaq: AVEO) today announced that the U.S. Food and Drug Administration (FDA) has approved Fotivda (tivozanib) for the treatment of adults wit

Latest News NDA News 1694
• Read All

Pfizer and BioNTech Publish Preclinical Data from Investigational COVID-19 Vaccine Program in Nature

New York, NY and Mainz, Germany, February 1, 2021 (GLOBE NEWSWIRE) -- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that preclinical data in non-human primate and mouse models

Latest News Clinical News 1635
• Read All

CureVac and Rentschler Biopharma to Ramp Up Production of COVID-19 Vaccine CVnCoV

Tübingen / Laupheim, Germany and Boston / Milford, MA, USA, February 1, 2021 -- CureVac NV (Nasdaq: CVAC), a biopharmaceutical company engaged in clinical trials to develop a new class of drugs based

Latest News Clinical News 1668
• Read All

Clover Biopharmaceuticals Announces Publication of Phase 1 Clinical Trial Data for its Adjuvanted COVID-19 Vaccine Candidates in The Lancet

CHENGDU, China, February 1, 2021 -- Clover Biopharmaceuticals (Clover), a global clinical-stage biotechnology company committed to developing transformative biologics as vaccines and therapeutics for

Latest News Clinical News 1718
• Read All

Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate

EMERYVILLE, CALIFORNIA and CHENGDU, CHINA, February 1, 2021 -- Clover Biopharmaceuticals (Clover), a global clinical-stage biotechnology company committed to developing transformative biologics as vac

Latest News Clinical News 1601
• Read All

COVID-19 Vaccine AstraZeneca Authorised for Use in the EU

29 January 2021 -- AstraZeneca’s COVID-19 vaccine has been granted a conditional marketing authorisation (CMA) in the European Union (EU) for active immunisation to prevent COVID-19 caused by SARS-CoV

Latest News Clinical News 1523
• Read All

Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial

NEW BRUNSWICK, N.J., January 29, 2021 -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating that t

Latest News Clinical News 1633
• Read All

New Amivantamab Data from CHRYSALIS Study Show Robust Clinical Activity and Durable Responses in Patients with Metastatic or Unresectable Non-Small Cell Lung Cancer and EGFR Exon 20 Insertion Mutations

January 28, 2021 (RARITAN, N.J.) -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 1 CHRYSALIS study, which evaluated amivantamab in patients wit

Latest News Clinical News 1891
• Read All

COVID-19 Vaccine AstraZeneca Recommended for Use in the EU

29 January 2021 -- AstraZeneca’s COVID-19 vaccine has been recommended for conditional marketing authorisation (CMA) in the European Union (EU) for active immunisation to prevent COVID-19 caused by SA

Latest News Clinical News 1490
• Read All

Pfizer and BioNTech Publish Data on COVID-19 Vaccine-Induced Antibodies’ Ability to Neutralize SARS-CoV-2 U.K. Strain Pseudovirus in Cell Culture in Science

New York, NY and Mainz, Germany, January 29, 2021 -- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that data from an in vitro study on the capability of sera from individuals

Latest News Clinical News 1612
• Read All

Amgen's Investigational KRAS G12C Inhibitor Sotorasib Demonstrated Rapid, Deep And Durable Responses In Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

THOUSAND OAKS, Calif., Jan. 28, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced results from the Phase 2 cohort of the CodeBreaK 100 clinical study evaluating investigational sotorasib (AMG

Latest News Clinical News 2252
• Read All
News
- CanalLotus Biotech -
Int'l Clinical Service Expert

We are the leader
Because of our professionism